faculty photo

Robert Gross, MD, MSCE

Professor of Medicine
Department: Medicine

Contact information
804 Blockley Hall
Center for Clinical Epidemiology and Biostatistics
University of Pennsylvania, Perelman School of Medicine
423 Guardian Drive
Philadelphia, PA 19104-6021
Office: 215-898-2437
Fax: 215-573-5315
Education:
BA (Italian)
Cornell University , 1986.
MD
Cornell University, 1991.
MSCE (Pharmacoepidemiology)
University of Pennsylvania, 2000.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Selected Publications

Tsima BM, Opondo P, Mosepele M, Mautle E, Bilker WB, Gross R: Prevalence of the metabolic syndrome and associated factors among inpatients with severe mental illness in Botswana: a cross-sectional study. BMC Cardiovascular Disorders 2022 (in press).

Hoskins K, Sanchez AL, Hoffacker C, Momplaisir F, Gross R, Brady KA, Pettit AR, Zengraf K, Mills C, Coley D, Beidas RS : Implementation Mapping to Plan for a Hybrid Trial Testing the Effectiveness and Implementation of a Behavioral Intervention for HIV Medication Adherence and Care Retention. Frontiers in Public Health 2022 (in press).

Martei YM, Narasimhamurthy M, Setlhako DI, Ayane G, Ralefala T, Chiyapo S, Gross R, Shulman LN, Grover S, DeMichele A : Relative Dose Intensity and Pathologic Response Rates in Breast Cancer Patients with and without HIV Who Received Neoadjuvant Chemotherapy JCO Global Oncology 2022 (in press).

Bien-Gund CH, Shaw PA, Agnew-Brune C, Baugher A, Brady KA,* Gross R* for the NHBS Study Group *equal work by authors : HIV self-testing and risk behaviors among men who have sex with men in 23 US cities, 2017. JAMA Network Open 2022 (in press).

Motlokwa PK, Tsima BM, Martei YM, Ralefala T, Galebole F, Stephens-Shields AJ, Grover S,* Gross R* * equal contribution by authors : Disparities in Oral Cancer Stage at Presentation in a High HIV Prevalence Setting in Sub-Saharan Africa JCO Global Oncology 2022 (in press).

Avihingsanon A, Hughes MD, Salata R, Godfrey C, McCarthy C, Mugyenyi P, Hogg E, Gross R, Cardoso SW, Bukuru A, Makanga M, Badal-Faesen S, Mave V, Wangari Ndege B, Nerette Fontain S, Samaneka W, Secours R, Van Schalkwyk M, Mngqibisa R, Mohapi L, Valencia J, Sugandhavesa P, Montalban E, Munyanga C, Chagomerana M, Santos BR, Kumarasamy N, Kanyama C, Schooley RT, Mellors JW, Wallis CL, Collier AC, Grinsztejn B for the A5288 Study team: Third-line antiretroviral therapy including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR) is well tolerated and achieves durable virologic suppression over 144+ weeks in resource limited settings: ACTG A5288 strategy trial. Journal of the International AIDS Society 2022 (in press).

Cioe PA, Schnoll R, Hoeppner BB, Gross R, Hitsman BL, Leone FT, Ashare R, Vilardaga R, Tashima K, Pinkston M, Kahler CW: The Impact of the COVID-19 Pandemic on Stress, Isolation, Smoking Behaviors, and Motivation to Quit in People with HIV who Smoke. AIDS and Behavior 2022 (in press).

Mannathoko N, Mosepele M, Gross R, Smith R, Alby K, Glaser L,Richard-Greenblatt M, Sharma A,Jaskowiak-Barr A, Cressman L, Sewawa K, Cowden L, Reesey E, Otukile D, Paganotti G, Mokomane M, Lautenbach E : Colonization with Extended-Spectrum Cephalosporin-Resistant Enterobacterales (ESCrE) and Carbapenem-Resistant Enterobacterales (CRE) in Healthcare and Community Settings in Botswana: An Antibiotic Resistance in Communities and Hospitals (ARCH) Study International Journal of Infectious Diseases 2022 (in press).

Arens Y, Bilker WB, Han X, Plankey M, Ware D, Friedman MR, D’Souza G, Stosor V, Shoptaw S, Schnoll RA, Tyndale RF, Ashare R*, Gross R* *equal contribution by authors: HIV Infection Does Not Explain Higher Nicotine Metabolism in People Living with HIV. JAIDS 2022 (in press).

Lowenthal ED, Ohrenshall R, Moshashane N, Bula B, Chapman J, Marukutira TC, Tshume O, Gross R, Mphele S. : Reasons for Discordance between Antiretroviral Adherence Measures in Adolescents. AIDS Care 34(9): 1135-1143, Sep 2022.

back to top
Last updated: 11/29/2022
The Trustees of the University of Pennsylvania